PepGen Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ananda Ghosh from H.C. Wainwright maintained a Buy rating on the stock and has a $20.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ananda Ghosh has given his Buy rating due to a combination of factors tied to PepGen’s lead DM1 program, PGN-EDODM1, and its upcoming 1Q 2026 multiple-ascending dose (MAD) readout. His discussions with disease experts strengthened his conviction that the 5 mg/kg dosing regimen is likely to remain within a comfortable safety margin, supported by prior single-ascending dose experience at substantially higher levels. The absence of key toxicity issues that have hindered other peptide-conjugated antisense programs, along with renal findings that specialists consider short-lived and manageable, contributes to his view that safety concerns are largely contained. These elements together support an expectation that the MAD trial can advance without major safety-driven disruptions, an important de-risking milestone for the program.
Ananda’s positive stance also reflects a belief that PepGen’s DM1 asset could deliver category-leading efficacy. The roughly 53% splicing correction seen in early data is viewed by key opinion leaders as an unusually strong biomarker response, exceeding what is typically observed in comparable early-stage therapies and suggesting molecular advantages over rival approaches. Experts further emphasized that the drug’s allele-selective mechanism may offer better long-term tolerability, enhancing its competitive positioning. Finally, the validation of vHOT as a clinically relevant endpoint—where even modest time improvements can translate into greater functional independence—supports the potential for meaningful real-world benefit, reinforcing his Buy recommendation on the stock.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PEPG in relation to earlier this year.